LINKÖPING, Sweden, November 5, 2026 – AMRA Medical has contributed to four studies being presented at AASLD’s The Liver Meeting 2026 in Denver, November 5–9. The research examines muscle health across chronic liver disease and cirrhosis using MRI-derived body composition measurements.
Across the studies, researchers from AMRA and our brilliant collaborators investigated relationships between muscle volume, muscle fat infiltration, and outcomes including long-term adverse events, post-transplant hospital burden, frailty, and neurocognitive function.
Two of the studies focus on clinical outcomes. In the first study, MRI-based volumetric thigh muscle measurements of myosteatosis and muscle volume z-score were independently associated with adverse clinical outcomes. A second study examined patients with cirrhosis evaluated for liver transplantation. Among those who underwent transplantation, greater pre-transplant muscle volume z-score was associated with fewer hospital and ICU days, shorter time to discharge, and fewer readmissions within one year.
Two additional studies examined muscle health in compensated MASH cirrhosis. One found that frailty varied across body composition phenotypes characterized by differences in muscle volume, muscle fat infiltration, and adipose tissue. The identified groups were otherwise not distinguishable by liver stiffness, spleen stiffness, or liver function. Another study examined neurocognitive function and found relationships between muscle fat infiltration and measures of psychomotor function and cognitive flexibility.
Together, these four studies apply MRI-derived muscle measurements across different liver disease populations and clinical questions, from longitudinal outcomes in chronic liver disease to post-transplant hospital burden, frailty, and neurocognitive function in cirrhosis.
Poster 1619
Adipose and Muscle Compartment Based Endotypes Reveal Sexual Dimorphism and Differential Effects on Frailty Indices in Cirrhosis Due to Metabolic Dysfunction Associated Steatohepatitis (MASH)
Date: Thursday, November 5 | Time: 12-1pm
Poster 2380
Predicting 7-Year Outcomes in Chronic Liver Disease: A Comparison of L1-Derived and Whole-Body MRI Muscle Metrics
Date: Friday, November 6 | Time: 1-2pm
Poster 2552
Lower MRI-Derived Muscle Volume Z-Score Is Associated With Greater Post-Transplant Hospital Burden in Patients With Cirrhosis Evaluated for Liver Transplantation
Date: Friday, November 6 | Time: 1-2pm
Poster 3425
Spleen Stiffness and Severity of Muscle Fat Quantity Are Independent Determinants of Neurocognitive Function in Compensated Cirrhosis Due to Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD)
Date: Saturday, November 7 | Time: 1-2pm
The studies add to AMRA’s growing evidence base across liver disease and demonstrate the use of MRI-derived muscle measurements across participants and stages of disease. AMRA looks forward to sharing the research alongside our collaborators in the field at TLM 2026!
Attending TLM 2026? Be sure to connect with our team onsite, or reach out to us at info@amramedical.com.
About AMRA Medical
AMRA Medical is a global leader in health informatics, pioneering the field of fat and muscle analysis with proprietary, MRI-based technologies. Our gold-standard platform delivers highly precise and standardized biomarkers, providing an advanced understanding of metabolic and musculoskeletal health that surpasses conventional measures of muscle and fat. These insights play a critical role in optimizing clinical trial design, improving endpoint selection, and supporting data-driven decision-making in both research and clinical practice.
MEDIA CONTACT
Melinda Perjons, Communication Strategist
melinda.perjons@amramedical.com